call. call everyone third afternoon Thank Thank our you, the you on And, quarter XXXX Marek. good conference today. for to joining us for
a third on detail reviewing and moments investors you As a few We'll remarks. have p.m., financial results also this press prepared and that time many and call, of we on quarter. X for questions ago, spending highlighting those will in after know, be our the issued our release analysts both at operational some
programs We're those both For that artificial data In at biotech an understanding, the oncology tool oncology growing a platform drug for also few develop happening transformation and powerful that of of proprietary that's multiple for accelerating we very and development the today tumor the is This therapies. are enabled leverages and response discovery. cancer a targeted unique to that company learning rescue stage modeling to in the very of a are machine cancer patient investors new drug has therapies. power and prediction and are drugs. machine to development intelligence one biotechs regard, story, clinical AI-based the of our and Lantern and forefront this the we rapidly
ahead XXth, began we XXX Shortly announced July was advancing for I end our new previous points, developing earnings billion before call, both million our announce six in team very in our team to of data for points. our data to have data consultants, actually these prediction. over our precision RADR cross the billion major been should on response I'm sets reach XXXX. employees months milestone curated last even oncology our also And development pleased the of development X meaningful trading indicated year. we our billion several data, now This has drug this months Our This point development, drug hard program, billion we surpassed to crossed roughly expect very AI is that mark that oncology advancing schedule. proprietary and June, members, actually, of drug while X during lab and X also and for drug X.X important platform. -- working we've getting team collaboration, platform plan. another after during ahead been more onboarding specifically the quarter And manufacturing, data past our that milestones new but for
selecting, understand precision, Our team the more and and data. also certain And and powerful. only making billion risk, cancer data engine more where develop has tagging made now and reduced our better to This compounds and importantly, to more work at a now how rapid in will cleaning, milestone, efficient curating progress much and our with Company more much, tremendous therapies getting data this allow pace. even greater the is point
into of experiments and share exponentially, relevance results we're also continue to and of of because lab from data, from system grow our and the back data collaborations feeding quality our partnerships. the Beyond the the merely amount the data own
is combined And will franchise. the the program data the quality business targeted benefit our every identifying pipeline learning platform an are RADR important enables accelerated core of of us in oncology that datasets, add our stands This core or drug of are sensitivity are activity XX algorithms, types outcome that oncology additional development really genomic RADR’s growth very we what enable the to drug sets important confident to our alongside to drug our derisked AI that our the AI Our growing with is while from patient XX process, streamline quantity path. The machine patient and also to of and targeted RADR mechanisms things. and of What driver our development our therapies? value And two sensitivity drive at development. model, the biomarkerly or the defined one to at months. drug? power genetically us essential drug to will the defined and
with During our make golden approaches to AI and development. acceleration golden for and cancer is of drive And the harnessing era and This complex to responsive I resources, we patients. that our today cloud an relevant experiencing pipeline true large and are machine-driven a beginnings availability for solving importantly last along and data, intelligence, data a scale of problems sometimes living we're computing in earnings where talent, of of call, the artificial especially unknown mentioned to and and age power, capabilities sequencing, trends meaningful have results on-demand accelerate this algorithms all age highly aligned of most reality. drug in the analytics, investors
previous follow clinical you through as development new those and efforts, therapies oncology abandoned just small pipeline beginning developed stage that of our identified prior experience efforts as story, we we biomarker to that For our potential have extensive after Lantern of owners’ or have following our includes compounds discovery we are molecule acquired well that late failures. that have assets
and and and And quantity Our rise. of value to ability drug our beyond RADR confident of enduring an transform AI data above model points grow, billion platform RADR business to that as development goes of efforts. X continues the underpins quality these each the we’re will develop
these that LP-XXX, both into we During trials. very the help are quarter, serve potency. for generate for develop cancer aggressively leading we're our as getting leverage nanomolar with Collaboration agent collaborations, preclinical on and trials the eventually as two entered asset to core into to which help clinical a important working a strategy trial DNA-damaging such us third data, clinical is for clinical It's to our drugs. insights, centers sites
during announced quarter University, were with past for pancreatic we that Fox collaborations Cancer Center with Georgetown cancer, Chase prostate cancer. Our and in the
collaborations about LP-XXX. the a from In collaboration talk me what phase we launched of for each little of expect these each. next Georgetown, and we Let bit
Fox lines to This potentially driver to a And with patients protein potent targeted expert patients that PTGRX. collaboration sensitivity Georgetown joint is important an use compelling both ultimately cancers Chase the stage tumors upcoming gene of that to help with program in and of of the in efficacy also agreement advances collaboration clinical save animal gene activity be program deficient. X as further drug will significantly Company in personalize to to clinical could The therapy accelerating activity develop development pancreatic successful the been help The antitumor of lead of therapy role validating linked therapeutics to next costs, was if Astsaturov to driving cancers. Dr. The cancers, LP-XXX trials. pancreatic prior believe with prostate asset. as genetically the potential will The be hormone-refractory cancer. to world of there are targeted cancers. or in an in personalized correlates cancer under treatment which signature in and gene damage allow a a that genomic specializes Georgetown again, The Cancer overexpression prostate of of expected relevant, detailed cell in subtypes of robust biologically The in both the of mechanism metastatic focus in for this cancer. for can oncology cancers this improve Georgetown increased he on Chase of DNA and shows now, The of market. of in renowned inform innovative stage research objective repair will recognized these we are of We will research antitumor we Fox drug confirmatory to millions dollars pathways at key can will to the of benefits the larger Philadelphia Fox set commercialization began in of overexpress Chase, investigator And to LP-XXX AI-driven as PTGRX and specific the in led the cancers signature trials. of was with a that approach DNA-damage signature collaboration great in fashion while is our biologically acquisition gene. and of research pinpoint that guide could that research Phase molecular solid fourth and survival. their focus potentially in in models, in also phase action ongoing well is use gene activities The program choice the further relevant, LP-XXX pancreatic LP-XXX initiated therapy and development provide prostate completing drug and at PDS in first subtypes information of trials. And express the robust us to the internationally models a this molecular goal the seek that create drug, the Lantern's to this by and very-specific a path cancer validation Dr. where involve This Igor collaboration these in very-underserved the the pathways prostate in make research has actually typically experience evidence investigating and Banerjee, of of that cancer, the second be it PTGRX. have the and cancer. dependent pathways. the edited in collaboration repair we that of very The personalized option generated Center being the public, work and is in that has XXXX, on signaling dose highly used development prostate GI defined also over quarter of biomarkers we research a that a clinical enzyme a believe is the a and Partha the for as researcher Ultimately, combinations that in
collaboration to see expect in but initial beginning use from collaboration, that we're early that's the of from on data best results informing actually, our thoughts this We QX already LP-XXX.
blood data call, brain last public, is demonstrating and we solid crossing very and did also was our During a going talked annulments. the crossing This LP-XXX brain that the We fronts. validated two prior hypothesis blood would current about had valid ahead think high care the nanomolar in which so, generated cross is important model being we past the that have by the and barrier work in-silico how demonstrated in-silico ability biology that we the in done brain lab of other to a by that was gathered world of on a barrier. quarter that LP-XXX potency to done glioblastoma. in did validation prior what We XD models replicated from blood the standard wet actual that the blood barrier now using LP-XXX the real equivalent are brain we’ve we we doing moved GBM evidence and of patients. this we and And further drugs to about used is barrier permeability LP-XXX biology, temozolomide,
intact We also not the functional. brain barrier, crosses validated viability, neuronal it LP-XXX and that cell cells compromise does while blood leaving
development million alone, to develop that's you platform that that are in LP-XXX, in time biology them to new validation molecule and is XX% very our asset meaningful very several cancer multiple and partnered lab to through our refractory Phase small X dual economic partnered drug asset, and metastatic really the we getting value-enhancing believe usually biomarker it drug using of further most in fraction drug with era and opportunity great mature by and targeted computational also sales. can than to which growing candidates be Therapeutics receive and genomically historical novo our scale an may a for market significant are other less Allarity for current first that hormone That's advances potential drug over prostate companies, collaboration experiments, participation. is coming candidates for data And therapy dollars know, us believe AI that with a a emblematic with a to also in the this program AI biomarker candidates or being de more time be cost we we for potential rescuing to currently that the drug candidates, to having a in guided GBM, pharma cancer. scientific on drug meeting our year, the bring joint developing used what to And places of and hundred of is believe serial not we and cost our we'll progress where drugs, provide much make of derisk are in As front a and highly development conflict. the LP-XXX we later the drug continuous also cancer can and our targeted. identify, using well. committee pursue drug this important a Allarity, drugs which position including Together, approach platform and us next associated has quarter, very in on This rescue large but of with we position portfolio should AI develop and programs driven and as genomics development, We in that milestones that discovery to data be that the perspective. strategy, traditional believe a U.S. updates driven, allows -- to provide in which transformational shareholders or the and trial advance one has tends we be develop believe for and trials
I'll the Margrave, results. quarter of Lantern’s for a over call Now, David our hand to David? third CFO, review financial
